Guideline: IVIg effective for certain nerve and muscle disorders

March 26, 2012

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology. The guideline is published in the March 27, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

IVIg is a type of immunotherapy that fights the misdirected immune system. It is not well understood exactly how IVIg works, but it likely regulates an overactive immune system. Immune globulin is a protein in human blood that likely links itself with antibodies or other substances directed at the .

According to the guideline, strong evidence shows that IVIg effectively treats Guillain-Barré syndrome, a rare disorder in which the body's attacks the peripheral nervous system, causing tingling and weakness in the arms and legs. The evidence shows that IVIg works as well as the treatment called plasma exchange to treat GBS.

Strong evidence also shows that long-term use of IVIg can help treat CIDP, which is the chronic counterpart of GBS and can affect nerves in the arms and legs and other parts of the body.

"Serious side effects are rare with IVIg, but there is a risk of kidney failure and a condition that causes the blood to be more likely to form clots," said guideline lead author Huned S. Patwa, MD, of Yale University and the VA Connecticut Healthcare System in West Haven and a member of the American Academy of . "It is important to work with your doctor when deciding whether to use IVIg for a neuromuscular disorder."

The guideline also found that IVIg is effective in helping to treat moderate to severe forms of myasthenia gravis and a rare condition known as multifocal motor neuropathy. It may also be helpful in treating neuromuscular disorders known as nonresponsive dermatomyositis and Lambert-Eaton myasthenic syndrome.

Explore further: Better and more affordable treatments for sufferers of autoimmune diseases

Related Stories

Costly treatment 'ineffective for babies'

September 30, 2011

(Medical Xpress) -- A worldwide study involving University of Sydney researchers has concluded that a costly and controversial treatment for neonatal sepsis is ineffective.

Recommended for you

After blindness, the adult brain can learn to see again

October 25, 2016

More than 40 million people worldwide are blind, and many of them reach this condition after many years of slow and progressive retinal degeneration. The development of sophisticated prostheses or new light-responsive elements, ...

The current state of psychobiotics

October 25, 2016

Now that we know that gut bacteria can speak to the brain—in ways that affect our mood, our appetite, and even our circadian rhythms—the next challenge for scientists is to control this communication. The science of psychobiotics, ...

Can a brain-computer interface convert your thoughts to text?

October 25, 2016

Ever wonder what it would be like if a device could decode your thoughts into actual speech or written words? While this might enhance the capabilities of already existing speech interfaces with devices, it could be a potential ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.